Benitec Biopharma (BNTC) vs Fulcrum Therapeutics (FULC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Benitec Biopharma (BNTC) has outperformed Fulcrum Therapeutics (FULC) over the past year, losing 34.8% versus a loss of 60.3%. Over five years, BNTC leads with a -85.3% price change compared with -85.9% for FULC. Benitec Biopharma is the larger company by market cap ($307.0 million vs $286.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTC | FULC |
|---|---|---|
| Share price | $8.80 | $3.75 |
| Market cap | $306.97M | $286.11M |
| 1-day change | -2.11% | +2.18% |
| YTD return | -33.26% | -67.55% |
| 1-year return | -34.76% | -60.28% |
| 5-year return | -85.27% | -85.88% |
| EPS (TTM) | $-0.98 | $-1.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.76 | $15.74 |
| 52-week low | $8.52 | $2.83 |
| Distance from 52-week high | -47.49% | -76.18% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +176.48% | -2.13% |
| Average volume | 152.08K | 1.53M |
| Shares outstanding | 34.88M | 76.30M |
| Employees | 24 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BNTC has outperformed FULC by 25.5 percentage points over the past year.
About Benitec Biopharma
BNTC stock →Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct.
Health Care · Biotechnology: Pharmaceutical Preparations · 24 employees
About Fulcrum Therapeutics
FULC stock →Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
BNTC vs FULC FAQ
Which is bigger, Benitec Biopharma or Fulcrum Therapeutics?
Benitec Biopharma (BNTC) is larger, with a market capitalization of $306.97M compared with $286.11M for Fulcrum Therapeutics (FULC).
Which stock has performed better over the past year, BNTC or FULC?
BNTC returned -34.76% over the past 12 months, compared with -60.28% for FULC (price return, excluding dividends). Past performance does not predict future results.
Are Benitec Biopharma and Fulcrum Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.